GTBP GT Biopharma Inc

GT Biopharma, Inc. engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1615, OXS-3550, OXS-3550, PainBrake, GTP-004, and GTP-011. The company was founded in 1965 and is headquartered in Beverly Hills, CA.

$3.29  +0.14 (4.44%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1969
Outstanding shares:  30,582,354
Average volume:  415,951
Market cap:   $96,334,415
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36254L209
ISIN:        US36254L2097
Sedol:      BMBZM12
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.13
PS ratio:   0.00
Return on equity:   -125.39%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy